Abstract
Background:
With the advent of highly effective anti-hepatitis C virus (HCV) drugs, efforts to identify infected cases, high-risk groups, and associated risk factors have become the focus of current control measures.Objectives:
To determine the prevalence of the HCV antibody among diabetics and patients with lymphoproliferative disorders (LPD) who presented to the outpatient clinics of a university hospital and its associated risk factorsPatients and Methods:
Consecutively consenting patients who had been previously diagnosed with diabetes mellitus and LPD at the outpatient department of the Lagos State University teaching hospital were recruited. A case record form was used to extract their demographics and physical examination findings as well as any risk factors for HCV infection; blood was also drawn to run a serological assay for the HCV antibody. All data were collated and analyzed using the Statistical Package for the Social Sciences version 20. Student T-test, Chi square, and logistic regression were some of the inferential statistics used in addition to descriptive statistics.Results:
In all, 438 patients (405 diabetics and 33 patients with LPD) were recruited. Their ages ranged from 17 - 87 years with a mean + Standard deviation of 59.61 + 11.859 years. The prevalence of hepatitis C among the diabetic subgroup was 0.7%, while the antibody was present in 9.1% of the LPD patients. The occurrence of the HCV antibody was, however, not significantly associated with age, sex, educational level, or marital status (P > 0.05). Having multiple sexual partners was identified as the only significant risk factor for hepatitis C (OR = 9.148; P = 0.017).Conclusions:
This survey suggested that a higher HCV prevalence exists in this population than is currently reported in the general population, and having sex with multiple partners was a risk factor for HCV infection.Keywords
Hepatitis C Prevalence Diabetes Mellitus Lymphoproliferative Disorders
1. Background
The hepatitis C virus (HCV) is an RNA virus that belongs to the family of flaviviruses; it is an important cause of liver disease worldwide and is estimated to affect over 150 million people. HCV is a leading cause of chronic liver disease, including liver cirrhosis, primary liver cell carcinoma (PLCC), and liver failure, and is an indication for liver transplantation, especially in the Western world (1, 2). In Nigeria, 18.7% - 38% of liver cancer patients carry markers of HCV (3).
The virus is parenterally transmitted; risk factors include blood transfusion, previous surgical and dental procedures, sharing of sharps (including tattooing/scarification and intravenous drug use (IDU) and, to a lesser extent, perinatal and sexual contact. Iatrogenic factors have also been blamed in some communities with a very high prevalence of HCV, like Egypt and Cameroon (2, 4).
The results of seroprevalence studies of HCV in Nigeria vary depending on the study population and also the geographical setting, with higher rates along the Eastern border and in some northern regions (5). The overall prevalence of HCV in a population survey of 4862 respondents in the Lagos state was 0.1% in 2014 (6) while the overall prevalence was 0.9% in an industry-sponsored nationwide survey involving 5,558 working-class adults conducted from 2010 - 2012 (7).
However in an earlier institution-based study in Nigeria, the HCV antibody prevalence was 4.7% among 360 outpatients in a university hospital, and no risk factors were significantly associated with it (8). The center for disease control (CDC) had previously recommended risk-based testing for HCV infection (9).
Patients with liver disease are known to have a higher prevalence of glucose intolerance, and preliminary studies suggest that HCV infection may be an additional risk factor for the development of diabetes mellitus because diabetics have an increased frequency of HCV infection (10, 11). A significant association has been reported to exist between hepatitis C and lymphoproliferative disorders (12) as well. Chronic hepatitis C virus infection has been linked with the development of lymphoproliferative disorders (LPDs); the prevalence of LPDs in individuals with HCV-induced chronic liver disease is greater than that of the normal healthy population (13).
Currently, newer drugs have shown great promise in eradicating this viral infection; efforts to identify infected cases as well as high-risk groups and their associated risk factors have become the focus of recent control measures. It is hoped that this study may help to document the burden of hepatitis C and its associated risk factors in these special populations, which may make them a priority group in current control measures.
2. Objectives
The purpose of this study was to determine the prevalence of the HCV antibody among diabetic and LPD patients attending the outpatient clinics of the Lagos State University hospital and associated risk factors in patients who test positive for the antibody.
3. Patients and Methods
This study was conducted in the Outpatient department of the Lagos state University teaching hospital from January to December 2014; consecutive consenting patients who had been previously diagnosed with diabetes mellitus (DM) or LPDs were recruited into the study until the desired sample size of 438 was achieved. The diagnosis of DM was based on the IIDF/WHO criteria (14), while that of LPDs was based on histological findings and/or immunohistochemistry (15). Patients who were too ill to comply with the study protocol or who refused to consent were excluded from the study.
A case record form was used to extract information, including demographics, risk factors for HCV acquisition (4), and diabetic and lymphoma history; blood was then collected from each subject for the HCV antibody testing. The latter was done using a Rapid Enzyme-linked Immunosorbent Assay (ELISA) kit, (Diaspot, Immune Assay Kit; DIA Source ImmunoAssays S.A., Louvain-la-Neuve, Belgium). The Diaspot kit for hepatitis C has a specificity of 98.6% and a sensitivity of 99%.
All data were collated and analyzed using the statistical package for the social sciences (SPSS) version 20. Student T-test, Chi Square, and logistic regression were some of the inferential statistics that were included in addition to descriptive statistics.
4. Results
The study included 438 participants: 405 diabetics and 33 patients with lymphoproliferative disorders (20 had non-Hodgkin’s lymphoma (NHL), and the others were Hodgkin’s lymphoma (HL), chronic lymphocytic leukemia (CLL), multiple myeloma (MM), and B-cell lymphoma). Their ages ranged from 17 - 87 years with a mean + standard deviation (SD) of 59.61 + 11.859 years. The subjects consisted of 66% females, and more than 60% of them had at least a secondary school education. Most participants (70%) were married.
The prevalence of hepatitis C among the diabetic subgroup was 0.7%, while the rate in the lymphoma patients was 9.1%. (All LPD patients with HCV had NHL.) The occurrence of the HCV antibody was, however, not significantly associated with the age, sex, educational level, or marital status of the participants (P > 0.05; Tables 1 - 4).
Having multiple sexual partners was identified as the only significant risk factor for hepatitis C acquisition (odds ratio (OR): 9.148; P = 0.017; see Tables 5 and 6).
HCV Prevalence and Association With Demographics: A Comparison of the Mean Ages of Hepatitis C-Positive and Hepatitis C-Negative Patients
| Value | N | Mean | SD | SE | Student T-Test |
|---|---|---|---|---|---|
| Hepatitis C-positive | 6 | 55.830 | 17.509 | 7.148 | t (434) = 0.785 |
| Hepatitis C-negative | 430 | 59.660 | 11.782 | 0.568 | P Value = 0.433 |
Relationship Between Gender and HCV Antibody Presence
| Value | Hepatitis C-Positive | Hepatitis C-Negative | Total | Fisher’s Exact Test |
|---|---|---|---|---|
| Gender | χ2 (1) = 0.000, P = 1.000 | |||
| Female, No (%) | 2 (1.4) | 142 (98.6) | 144 (100.0) | |
| Male, No (%) | 4 (1.4) | 281 (98.6) | 285 (100.0) | |
| Total, No (%) | 6 | 423 |
Relationship Between Patients’ Educational Level and Hepatitis C
| Value | Hepatitis C-Positive | Hepatitis C-Negative | Total | Chi Square Test |
|---|---|---|---|---|
| Educational level | χ2 (3) = 4.422, P = 0.219 | |||
| No formal education, No (%) | 2 (4.0) | 48 (96.0) | 50 (100.0) | |
| Primary, No (%) | 2 (1.8) | 109 (98.2) | 111 (100.0) | |
| Secondary, No (%) | 0 (0.0) | 130 (100.0) | 130 (100.0) | |
| Tertiary, No (%) | 2 (1.5) | 135 (98.5) | 137 (100.0) | |
| Total, No (%) | 6 | 422 | 428 (100.0) |
HCV Antibody Presence and Marital Status
| Value | Hepatitis C-Positive | Hepatitis C-Negative | Total | Chi Square Test |
|---|---|---|---|---|
| Marital status | χ2 (3) = 7.104, P = 0.069 | |||
| Single, No (%) | 1 (8.3) | 11 (91.7) | 12 (100.0) | |
| Married, No (%) | 2 (0.7) | 304 (99.3) | 306 (100.0) | |
| Divorced, No (%) | 0 (0.0) | 10 (100.0) | 10 (100.0) | |
| Widowed, No (%) | 2 (2.6) | 75 (97.4) | 77 (100.0) | |
| Total, No (%) | 5 | 400 | 405 (100.0) |
| Value | Sig | Odds Ratio | 95% CI for EXP (B) | |
|---|---|---|---|---|
| Lower | Upper | |||
| Blood transfusion | 0.186 | 6.188 | 0.414 | 92.459 |
| Previous surgery | 0.637 | 1.896 | 0.133 | 27.061 |
| Multiple sexual partners (MSP) | 0.505 | 2.335 | 0.193 | 28.234 |
| Constant | 0 | 0.002 | ||
Logistic Regression to Identify the Risk Factors for Hepatitis C Among Diabetic and Lymphoma Patientsa
| Value | Sig | Odds Ratio | 95% CI for EXP (B) | |
|---|---|---|---|---|
| Lower | Upper | |||
| Previous surgery | 0.065 | 7.832 | 0.877 | 69.956 |
| Previous incarceration | 0.165 | 7.145 | 0.446 | 114.570 |
| Multiple sexual partners (MSPs) | 0.017 | 9.148 | 1.490 | 56.162 |
| Constant | 0 | 0.002 | ||
5. Discussion
The observed prevalence of an antibody to hepatitis C in diabetic subjects (0.7%) was similar to that reported (0.1%, 0.6%, and 0.9%) in recent population-based surveys (5-7) conducted in the same locality during the same period, while that of LPD (9.1%) was much higher. One explanation for this finding may be that despite previous reports, diabetics are actually not more predisposed to contracting hepatitis C infection, while HCV infection may be associated with an increased risk of LPDs. However, we were not able to decipher the time of acquisition of the HCV infection in relation to the onset of the lymphoma, as this was just a cross-sectional study. The sero-prevalence rates (5-7) in these population surveys are much lower that the estimated rates reported recently (2), which could indicate a lower disease burden than was estimated.
In addition to liver-related complications, HCV infection has also been implicated as an independent risk factor for cardiovascular disease (16) and, more recently, cerebral hemorrhage (17), which leaves diabetics or lymphoma patients with an HCV infection more prone to experiencing a severe outcome and would make them a priority population in the efforts to eradicate HCV.
In this study, sex with multiple partners was identified as the only risk factor for HCV antibody acquisition. This finding was in contrast to an earlier report that suggested that the risk factors for HCV were obscure in Nigeria, although that study was conducted in another geographical zone of Nigeria. However, the sexual route generally has been reported as a less likely route of transmission of HCV due to reports that indicated discordance rates among couples (18), except in cases of high-risk sexual behavior. The latter topic was not investigated in this present study. If this finding is confirmed in future studies, it would imply that those who have multiple sexual partners should be included in the high-risk population that requires HCV screening to stay in line with the recommendation of the CDC that those at risk of acquisition or who are already potentially infected should be screened (9).
This study was, however, limited by our inability to assay RNA in those positive for HCV antibody since earlier reports (19) have indicated that only about 70% of them are viremic. Nonetheless this study suggested that the higher prevalence of HCV infection in the LPD population makes these patients a priority for HCV screening in this era of HCV eradication with the newly available and highly effective anti-HCV therapy.
Acknowledgements
References
-
1.
WHO. Global Alert and response Hepatitis C. 2015. Available from: Http/www.WHO.int/csr/disease/hepatitis.
-
2.
Gower E, Estes C, Blach S, Razavi-Shearer K, Razavi H. Global epidemiology and genotype distribution of the hepatitis C virus infection. J Hepatol. 2014;61(1 Suppl):S45-57. [PubMed ID: 25086286]. https://doi.org/10.1016/j.jhep.2014.07.027.
-
3.
Bojuwoye BJ. The burden of viral hepatitis in Africa. West Afr J Med. 1997;16(4):198-203. [PubMed ID: 9473953].
-
4.
Karaca C, Cakaloglu Y, Demir K, Ozdil S, Kaymakoglu S, Badur S, et al. Risk factors for the transmission of hepatitis C virus infection in the Turkish population. Dig Dis Sci. 2006;51(2):365-9. [PubMed ID: 16534682]. https://doi.org/10.1007/s10620-006-3139-6.
-
5.
Nigerian centre for disease control/epidemiology division. Report of national survey for hepatitis B & C in Nigeria. Nigeria: Fed Min Health Nigeria; 2013.
-
6.
Chukwuma M, Alemma-Ozioruva A, Okechukwu O. Association of public health physician on behalf of lagos state min of health. Hepatitis b & c seroprevalence survey among residents of lagos state. 2014.
-
7.
Onyekwere CA, Hameed L. Hepatitis B and C virus prevalence and association with demographics: report of population screening in Nigeria. Trop Doct. 2015;45(4):231-5. [PubMed ID: 25515733]. https://doi.org/10.1177/0049475514560211.
-
8.
Obienu O, Nwokediuko S, Malu A, Lesi OA. Risk factors for Hepatitis C virus transmission obscure in nigerian patients. Gastroenterol Res Pract. 2011;2011. https://doi.org/10.1155/2011/939673.
-
9.
Centre for Disease control. Viral hepatitis-Hepatitis C information. 2015. Available from: http://www.cdc.gov/hepatitis/hcv/guidelinesc.htm.
-
10.
Guo X, Jin M, Yang M, Liu K, Li JW. Type 2 diabetes mellitus and the risk of hepatitis C virus infection: a systematic review. Sci Rep. 2013;3:2981. [PubMed ID: 25671325]. https://doi.org/10.1038/srep02981.
-
11.
Mason AL, Lau JY, Hoang N, Qian K, Alexander GJ, Xu L, et al. Association of diabetes mellitus and chronic hepatitis C virus infection. Hepatology. 1999;29(2):328-33. [PubMed ID: 9918906]. https://doi.org/10.1002/hep.510290235.
-
12.
Muhammad SK, Chandio MA, Soomro MA, Shaikh BA. Hepatitis c virus infection in non-hodgkin’s lymphoma: A case-control study. Hepat Mon. 2012;12(1):16-22.
-
13.
Idilman R, Colantoni A, De Maria N, Alkan S, Nand S, Van Thiel DH. Lymphoproliferative disorders in chronic hepatitis C. J Viral Hepat. 2004;11(4):302-9. [PubMed ID: 15230852]. https://doi.org/10.1111/j.1365-2893.2004.00480.x.
-
14.
Report of IDF/WHO consultation. Definition and diagnosis of diabetes mellitus. 2015. Available from: https://www.idf.org/webdata/docs/WHO_IDF_definition_diagnosis_of_diabetes.pdf.
-
15.
d'Amore F, Gaulard P, Trumper L, Corradini P, Kim WS, Specht L, et al. Peripheral T-cell lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015;26 Suppl 5:v108-15. [PubMed ID: 26314772]. https://doi.org/10.1093/annonc/mdv201.
-
16.
Negro F. Facts and fictions of HCV and comorbidities: steatosis, diabetes mellitus, and cardiovascular diseases. J Hepatol. 2014;61(1 Suppl):S69-78. [PubMed ID: 25443347]. https://doi.org/10.1016/j.jhep.2014.08.003.
-
17.
Chun-Hung T, Chih-Hsin M, Chung YH, Chia-Hung K. Increased risk of intracerebral hemorrhage among patients with hepatitis c infection. Medicine. 2015;94(46). https://doi.org/10.1097/MD.0000000000002132.
-
18.
Terrault NA, Dodge JL, Murphy EL, Tavis JE, Kiss A, Levin TR, et al. Sexual transmission of hepatitis C virus among monogamous heterosexual couples: the HCV partners study. Hepatology. 2013;57(3):881-9. [PubMed ID: 23175457]. https://doi.org/10.1002/hep.26164.
-
19.
Okwuraiwe AP, Salu OB, Anomneze E, Audu RA, Ujah IAO. Hepatitis C virus genotypes and viral ribonucleic acid titers in Nigeria. Nig J Gastroenterol Hepatol. 2012;4(2):67-72.